BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?
BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BioHarvest CEO talks Nasdaq uplisting, profit targets - ICYMI
BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week reported its financial results for 2024, showing a 99.00% year-over-year increase in revenue to 25.20 million US dollars. The company said fourth-quarter revenue was 7.30 million US dollars, up 62.00% compared to the prior year, and ahead of previously issued guidance.
BioHarvest shares rise after Q4 results show strong demand for VINIA products
BioHarvest Sciences Inc. (NASDAQ:BHST) reported a 62% year-over-year increase in fourth-quarter revenue, reaching $7.3 million, as the biotechnology company saw strong demand for its VINIA product lines and expanded its contract development and manufacturing organization (CDMO) services. Full-year revenue nearly doubled to $25.2 million, with gross margins improving by 1,000 basis points to 55%.
BioHarvest Sciences Inc. (BHST) Q4 2024 Earnings Conference Call Transcript
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Anthony Vendetti - Maxim Group Amit Dayal - H.C. Wainwright Hunter Diamond - Diamond Equity Research Susan Anderson - Canaccord Operator Greetings, and welcome to the BioHarvest Sciences Fourth Quarter 2024 Corporate Update Conference Call.
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.70 per share a year ago.
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BioHarvest Sciences appoints veteran technology leader to board of directors
BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) has announced the appointment of seasoned technology executive Sharon Malka as an independent director of the company. Malka brings extensive leadership experience to BioHarvest, with a background spanning international healthcare and technology companies.
BioHarvest Sciences positioned for ‘legacy year' in 2025, building on momentum with new innovations and strategic collaborations
BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) is poised to capitalize on key trends shaping the health and wellness industry in 2025, including a growing focus on sustainability, longevity-driven health solutions, and plant-based innovation. “The notions of sustainability, longevity, and the recognition of the power that exists in plants from consumers and industry are three critical trends that are really driving tailwinds,” Ilan Sobel, BioHarvest Sciences CEO, told Proactive.
BioHarvest Sciences CEO reflects on transformative 2024, outlines vision for future growth
BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) CEO Ilan Sobel has reflected on 2024 as “a year of transformation and growth” for the company. In a letter to shareholders, Sobel highlighted the launch of the company's Contract Development and Manufacturing Organization (CDMO) Services division as “the most transformational change in 2024” for BioHarvest.
BioHarvest Sciences CEO discusses Tate & Lyle partnership - ICYMI
BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) this week announced a significant move for the company, a partnership with Tate & Lyle to develop plant-based sweeteners. The collaboration aims to create botanical, plant-derived sweeteners that are sustainable, low-calorie, and offer superior taste.
BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q3 2024 Earnings Conference Call November 25, 2024 4:30 PM ET Company Participants Justin Meiklem - IR Ilan Sobel - CEO Bar Dichter - CFO Zaki Rakib - President of Botanical Synthesis CDMO Business Unit Conference Call Participants Hunter Diamond - Diamond Equity Research Operator Greetings, and welcome to the BioHarvest Sciences Third Quarter 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago.
